Why SNOMED CT? New platform presents a refreshed case for investing in the comprehensive clinical terminology

SNOMED International released today its refreshed SNOMED CT Case for Investment report.

London, United Kingdom, Dec. 16, 2021 (GLOBE NEWSWIRE) — SNOMED International released today its refreshed SNOMED CT Case for Investment report. Available on a new interactive platform, the Case for Investment presents evidence that SNOMED CT adds measurable value to a broad range of primary and secondary health processes leveraging SNOMED CT encoded data to enable improved patient outcomes. Through the narrative, the report provides accessible and understandable answers to questions such as, “what is SNOMED CT?”, ‘what makes SNOMED CT unique?’, “how and where is it in use globally?” and “why invest in SNOMED CT?”

SNOMED CT, the most comprehensive and multilingual clinical healthcare terminology in the world, possesses unique characteristics that differentiate it from other classifications and terminologies. Among these characteristics are SNOMED CT’s position as a core reference terminology, its clinically comprehensive 350,000+ concepts supported by a machine-readable semantic network, broad use and mandate in select countries.

Showcasing real world use and outcomes of SNOMED CT is the best way to demonstrate its value, understanding that SNOMED CT must be embedded in a clinical information system, health data & analytics platform or an interoperability solution for it to function. Through the Case for Investment, 10 examples of SNOMED CT use across data entry and integration, clinical information sharing, point of care analytics, population and management analytics and research domains have been featured. Ranging across different countries such as Australia, Canada, China, United Kingdom, United States, continued collection of additional SNOMED CT case studies remains an ongoing priority.

SNOMED International CEO, Don Sweete, commented on the development and outcomes of the Case for Investment. “There has been a tremendous evolution in SNOMED CT over the past 10 years and this report demonstrates the value that it offers healthcare systems and stakeholders worldwide” said Sweete. “With a complement of 41 Members that represent health systems globally, continuously refreshed knowledge and analysis on the nature, utility and value of standards like SNOMED CT can’t be overstated. Health system decision-makers need to be equipped with clear knowledge of how their investments in SNOMED CT translate into positive outcomes for the health of their nation’s citizens.”

In terms of conclusions, the report presents SNOMED CT as a scalable and “fit for purpose” clinical terminology, adhering to international criteria, data quality and suitability requirements. A part of the bigger picture, SNOMED CT is one of many contributing factors to improving patient outcomes, and studies show that the use of SNOMED CT-embedded systems can provide significant qualitative and quantitative patient outcome benefits.

Looking forward, SNOMED CT must also contemplate how it enables the future needs of medicine and research. A healthcare industry that is ever evolving, the future opportunities for SNOMED CT will be driven by new healthcare data sources and new healthcare technologies such as national cohorts, big data and AI, clinical genomics, phenomics and environment, etc.

Experience the breadth of the SNOMED CT Case for Investment through the organization’s interactive value platform at value.snomed.org.

Attachment

Kelly Kuru
SNOMED International
comms@snomed.org

Nikkiso Clean Energy & Industrial Gases Group devient membre ambassadeur de California Fuel Cell Partnership

TEMECULA, Californie, 15 déc. 2021 (GLOBE NEWSWIRE) — Nikkiso Clean Energy & Industrial Gases Group (Groupe), une filiale de Nikkiso Co., Ltd (Japon), est fier d’annoncer qu’il a rejoint le California Fuel Cell Partnership (CaFCP) en tant qu’ambassadeur.

Cette association travaille à établir 200 stations de ravitaillement en hydrogène d’ici 2025 en vue d’un avenir durable pour les voitures, les camions et les bus à zéro émission. Rejoindre le CaFCP s’inscrit dans l’engagement du Groupe à mener le changement vers un monde plus sain. En outre, le Groupe étend ses activités mondiales et ouvre une nouvelle installation d’ingénierie et de service à Houston et en Corée cette année, ainsi qu’un nouveau centre en Allemagne en 2022.

« Nous sommes ravis de faire partie du CaFCP pour fournir des alternatives énergétiques propres et nous sommes impatients de collaborer avec d’autres membres du CaFCP sur le marché du carburant hydrogène pour les piles à combustible », a déclaré Peter Wagner, PDG de Nikkiso Clean Energy & Industrial Gases Group.

Plusieurs nouveaux produits à base d’hydrogène sont en cours de développement, tels que les premières pompes mobiles à ravitaillement en hydrogène, les pompes à hydrogène alternatives haute capacité/haute pression et les stations de ravitaillement en hydrogène liquide conteneurisé. Ceci s’ajoute à leur capacité à fournir des projets d’ingénierie, des projets d’approvisionnement et des projets complets clés en main.

À PROPOS DE CRYOGENIC INDUSTRIES
Cryogenic Industries, Inc. (aujourd’hui membre de Nikkiso Co., Ltd) et ses entreprises membres fabriquent des équipements et de petites usines de traitement du gaz cryogénique pour les secteurs du gaz naturel liquéfié (GNL), des services d’entretien de puits et du gaz industriel. Fondée il y a plus de 50 ans, Cryogenic Industries est la société-mère d’ACD, de Cosmodyne et de Cryoquip, ainsi qu’un groupe administré en commun comptant une vingtaine d’entités opérationnelles.

Pour tout complément d’information, veuillez consulter les sites www.nikkisoCEIG.com et www.nikkiso.com.

Contact auprès des médias :
Anna Quigley
+1.951.383.3314
aquigley@cryoind.com

Clean Energy & Industrial Gases Group da Nikkiso torna-se membro embaixador da California Fuel Cell Partnership

TEMECULA, Califórnia, Dec. 15, 2021 (GLOBE NEWSWIRE) — O Nikkiso Clean Energy & Industrial Gases Group (Grupo), subsidiária da Nikkiso Co., Ltd (Japão), tem o orgulho de anunciar a sua entrada para a California Fuel Cell Partnership (CaFCP) como embaixador.

A associação está no processo de estabelecer 200 estações de abastecimento de hidrogênio até 2025 para um futuro sustentável para carros, caminhões e ônibus de emissão zero. A adesão à CaFCP faz parte do compromisso do Grupo de liderar a mudança para um mundo mais saudável. Além disso, o Grupo está expandindo suas operações em todo o mundo, com a inauguração novas instalações de engenharia e serviço em Houston e na Coréia este ano e um novo centro na Alemanha em 2022.

“Estamos contentes em fazer parte da CaFCP para fornecimento de alternativas de energia limpa e estamos prontos para colaborar com outros membros da CaFCP no mercado de hidrogênio de células de combustível”, disse Peter Wagner, CEO do Nikkiso Clean Energy & Industrial Gases Group.

Existem vários novos produtos de hidrogênio em desenvolvimento, como as primeiras bombas móveis de reabastecimento de hidrogênio, bombas de hidrogênio alternativo de alta capacidade/alta pressão e estações de reabastecimento de hidrogênio líquido em contêiner. Além da capacidade de fornecer projetos de engenharia, compras e turnkey completos.

SOBRE A CRYOGENIC INDUSTRIES
A Cryogenic Industries, Inc. (agora membro da Nikkiso Co., Ltd.) fabrica equipamentos de processamento de gás criogênico projetados e plantas de processo de pequena escala para as indústrias de gás natural liquefeito (GNL), serviços de poços e gás industrial. Fundada há mais de 50 anos, a Cryogenic Industries é a empresa controladora da ACD, Cosmodyne e Cryoquip, e de um grupo comumente controlado de aproximadamente 20 entidades operacionais.

Para mais informação, visite www.nikkisoCEIG.com e www.nikkiso.com.

CONTATO COM A MÍDIA:
Anna Quigley
+1.951.383.3314
aquigley@cryoind.com

Casio lance des modèles G-SHOCK en collaboration avec la série documentaire télévisée Matchday : Inside FC Barcelona

TOKYO, 15 décembre 2021 /PRNewswire/ — Casio Computer Co., Ltd. a annoncé aujourd’hui les dernières nouveautés de sa marque de montres antichocs G-SHOCK. Le GBD-H1000BAR et le GBD-100BAR sont des modèles de collaboration célébrant Matchday: Inside FC Barcelona, un documentaire sur le monde intérieur du célèbre club de football espagnol.

GBD-H1000BAR (left), GBD-100BAR (right)

Les modèles de base des deux nouvelles montres sont le GBD-H1000 et le GBD-100, tous deux issus de la gamme G-SQUAD. Les nouveaux modèles reprennent les couleurs bleu et grenat de l’équipe du FC Barcelone. Les bracelets, conçus pour évoquer les uniformes passés et présents de l’équipe, sont imprimées de la devise du club, « Més que un club » (« Plus qu’un club ») dans la langue catalane locale. Le GBD-H1000BAR est dotée d’une lunette en métal plaqué or ionique brillant comme une coupe de trophée de vainqueur, tandis que la boucle du bracelet des deux montres arbore les quatre bandes rouges du drapeau catalan. Un emballage spécialement conçu, également aux couleurs de l’équipe du FC Barcelone, est une touche finale digne de ces montres singulières.

GBD-H1000BAR / GBD-100BAR

Les deux nouvelles montres sont équipées d’un accéléromètre pour compter les pas et suivre les distances. Le GBD-H1000BAR est également équipé d’un moniteur de fréquence cardiaque et d’un suivi GPS. Les deux nouveaux modèles offrent également des fonctions de liaison mobile qui, lorsqu’elles sont associées à une application smartphone dédiée, favorisent la gestion quotidienne de la santé en permettant aux utilisateurs de consulter les journaux de vie avec des données sur le nombre de pas et les calories brûlées, les journaux d’activité, etc. L’écran LCD à mémoire en pixels (MIP) pour une visibilité exceptionnelle et le bracelet en uréthane souple, pour une ventilation et une flexibilité exceptionnelles, offrent un confort dans toutes les situations, de l’utilisation quotidienne aux entraînements intensifs.

Special packaging (GBD-H1000BAR [left]; GBD-100BAR [right])

Matchday: Inside FC Barcelona

Une série documentaire en huit épisodes centrée sur la saison 2018-2019 de l’un des clubs de football les plus adulés au monde. Du frisson de la victoire à l’agonie de la défaite, la série offre un aperçu des joueurs, de la philosophie et de la culture du FC Barcelone.

Photo : https://mma.prnewswire.com/media/1708036/image_1.jpg

Photo : https://mma.prnewswire.com/media/1708149/image_2.jpg

Photo : https://mma.prnewswire.com/media/1708038/image_3.jpg

Minimum Expenditure Basket in Malawi – Rounds 42: 15-19 November 2021 – A Look at Food Prices and Availability in Times of COVID-19

Highlights

• Round 42 data, which was captured between 15 and 19 November 2021, reveals a further increase on households’ minimum survival expenditure across all regions. The Survival Minimum Expenditure Baskets (SMEBs) rose by 2.0 percent in the urban areas; 2.5 percent in the rural Northern Region; 1.2 percent in the rural Central Region; and 4.0 percent in the rural Southern Region. Key commodities driving the increase included cooking oil, green vegetables and firewood.

• During this reporting period, the price of maize grain further decreased by 1.4 percent to MK 144 per kg, down from MK 146 per kg in the previous round, as farmers are offloading their stocks on the market to get money for the purchase of farm inputs.

• In the current round, beans were selling at a national average price of MK 1,108 per kg, slightly up (by 1.7 percent) from MK 1,090 in the previous round.

• Cowpea prices remained unchanged at MK 630 per kg, while pigeon pea prices marginally increased by 1.5 percent from MK 546 per kg in the previous round to MK 544 per kg in Round 42.

Source: World Food Programme

CDC Advisers Vote to Recommend mRNA COVID-19 Vaccines Over J&J’s

A panel of outside advisers to the U.S. Centers for Disease Control and Prevention on Thursday voted to recommend that Americans choose one of the other two authorized COVID-19 vaccines over Johnson & Johnson’s shot because of the rare but sometimes fatal cases of blood clotting.

The CDC’s Advisory Committee on Immunization Practices voted unanimously on the recommendation. The regulator still needs to sign off on the guidance.

Cases of thrombosis with thrombocytopenia syndrome (TTS), which involves blood clots accompanied by a low level of platelets, have previously been reported in recipients of the J&J vaccine. The highest reporting rates are in women under 50.

The CDC said that the rate of such incidents is higher than previously estimated in both women and men.

At least nine people have died following the blood clotting incidents in the United States, the CDC has said.

Members of the panel also said J&J’s vaccine is less effective in preventing COVID-19 than the other two authorized vaccines.

In a presentation to the committee, a leading J&J vaccine scientist said the vaccine generates a strong and long-lasting immune response with just a single shot.

“In the setting where many people do not return for a second dose or a booster, the durability of the single-shot Johnson & Johnson vaccine as a primary regimen could make a crucial difference in saving lives in the U.S. and around the globe,” J&J’s Dr. Penny Heaton said in the presentation.

J&J’s vaccine uses a technology based on a modified version of an adenovirus to spur immunity in recipients, while the other two authorized vaccines use messenger RNA technology.

J&J’s one-dose vaccine received emergency use authorization in March. In April, U.S. regulators paused administering the vaccine for 10 days to investigate the blood clotting.

A CDC scientist said on Thursday that the rate of deaths from TTS did not decrease after the pause in April.

Fewer Americans have received the J&J shot than the other two vaccines — by a significant margin. Out of more than 200 million fully vaccinated people in the United States, around 16 million received J&J’s vaccine, according to CDC data.

Source: Voice of America